Form 13-F position report

BIODESIX INC COM (DE)

Reported by MORGAN STANLEY

BDSXXXXX CUSIP 09075X108 Manager CIK 0000895421

Reported 7,435 shares, down 1,738 (18.9%) from the prior quarter.

Reported value -13.3%; share count -18.9% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2024
Shares 7,435 Quarter-end amount reported
Reported value $11,375 Fair value at quarter end
Consecutive quarters held 15 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 344000
2022-03-31 94000
2022-06-30 121000
2022-09-30 71000
2022-12-31 120053
2023-03-31 95232
2023-06-30 23527
2023-09-30 17630
2023-12-31 18649
2024-03-31 13118
2024-06-30 11375
2024-09-30 13234
2024-12-31 61622
2025-03-31 8050
2025-06-30 361
2025-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for BIODESIX INC COM (DE) held by MORGAN STANLEY.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Reduced 0 -1,278 (-100.0%) 0 $0 2025-11-14
Q2 2025 Reduced 1,278 -11,598 (-90.1%) < 0.01% $361 2025-08-15
Q1 2025 Reduced 12,876 -27,400 (-68.0%) < 0.01% $8,050 2025-05-15
Q4 2024 Added 40,276 +32,841 (441.7%) < 0.01% $61,622 2025-02-14
Q3 2024 Unchanged 7,435 0 (0.0%) < 0.01% $13,234 2024-11-14
Q2 2024 Reduced 7,435 -1,738 (-18.9%) < 0.01% $11,375 2024-08-14
Q1 2024 Reduced 9,173 -962 (-9.5%) < 0.01% $13,118 2024-05-15
Q4 2023 Reduced 10,135 -550 (-5.1%) < 0.01% $18,649 2024-02-13
Q3 2023 Reduced 10,685 -8,443 (-44.1%) < 0.01% $17,630 2023-11-15
Q2 2023 Reduced 19,128 -32,072 (-62.6%) < 0.01% $23,527 2023-08-14
Q1 2023 Reduced 51,200 -997 (-1.9%) < 0.01% $95,232 2023-05-15
Q4 2022 Reduced 52,197 -4,764 (-8.4%) < 0.01% $120,053 2023-02-14
Q3 2022 Reduced 56,961 -16,302 (-22.3%) < 0.01% $71,000 2022-11-14
Q2 2022 Added 73,263 +17,401 (31.1%) < 0.01% $121,000 2022-08-15
Q1 2022 Reduced 55,862 -9,315 (-14.3%) < 0.01% $94,000 2022-05-13
Q4 2021 Reduced 65,177 -43,228 (-39.9%) < 0.01% $344,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

59 managers reported BIODESIX INC COM (DE) for Q2 2024.

Managers reporting BIODESIX INC COM (DE) in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Telemark Asset Management LLC Added 8,282,490 +6,956,490 1.1% $12,672,210 3 qtrs
Soleus Capital Management L P New 6,111,964 +6,111,964 0.82% $9,351,305 1 qtr
AIGH Capital Management LLC Added 5,779,812 +2,458,727 2.75% $8,843,113 7 qtrs
Birchview Capital LP Added 5,696,113 +347,840 8.04% $8,700,887 15 qtrs
Sio Capital Management LLC New 4,347,855 +4,347,855 1.8% $6,652,218 1 qtr
Opaleye Management Inc Added 4,020,000 +3,485,343 1.41% $6,150,600 4 qtrs
Monashee Investment Management LLC New 3,260,879 +3,260,879 0.65% $4,989,145 1 qtr
VANGUARD GROUP INC Added 2,906,504 +2,098,576 < 0.01% $4,446,951 15 qtrs
PERCEPTIVE ADVISORS LLC New 2,173,880 +2,173,880 0.08% $3,326,036 1 qtr
FARALLON CAPITAL MANAGEMENT LLC New 1,878,175 +1,878,175 0.01% $2,873,608 1 qtr
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 14, 2024
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
4,957
Shared
0
None
2,478

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.